Race leadership team strengthened
Filed with ASX · · 4 pages · English
Earlier from Racura Oncology
- Strategic investors make further $1.5m investment in Race
- A$3m strategic investment from prominent biotech investors
- Extension of time to repay loan through share buy-back
- Impressive 40% response in Phase II Bisantrene AML Trial
- Managing Director Resignation
Later from Racura Oncology
- Prof Borje S Andersson appointed Chief Medical Officer
- Impressive Preclinical Bisantrene Breast Cancer Results
- Race AGM presentations and strategic update
- Race receives $387k R&D tax incentive refund
- Compelling Preclinical Breast Cancer Results
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology